Could Suicide Be Fostered Through the Potential Antidepressant Mechanism of Biological Agents? A Psychodermatological Approach to Existing Bibliography
Restricted accessReview articleFirst published online April, 2020
Could Suicide Be Fostered Through the Potential Antidepressant Mechanism of Biological Agents? A Psychodermatological Approach to Existing Bibliography
Bipolar disorder (BD) is a biological condition that affects between 2% and 5% of the population. Despite this, it is often underdiagnosed as unipolar depression, which increases the possibility of prescribing errors. This could foster episodes of inverse polarity (“switching”) which, in turn, raises the risk of suicide.
Objective:
This work reviews the existing literature for evidence that while biological agents could improve the mood of patients with psoriasis treated with these drugs, this same favorable antidepressant effect on humor may trigger a switch into mania, favoring attempted and completed suicide in undiagnosed bipolar patients treated for psoriasis with the abovementioned agents.
Method:
A systematic review of the literature was performed for evidence. Based on their titles and abstracts, 48 relevant articles from 18 countries in English, Spanish, and French from 2004 to 2019 were selected for this review.
Results:
Inherently, all antidepressants can be associated with treatment-emergent affective switch (TEAS). Biological agents may modify the neurotransmitter levels either improving or worsening the mood. A plausible hypothesis arises on the double-edged nature of biological agents: they would have an antidepressant effect that would be beneficial to treat the psychiatric comorbidity of the patient with psoriasis. However, this same antidepressant effect, in a patient with genetic vulnerability for depression with a concomitant inflammatory disease, could trigger a mood alteration.
Conclusion:
Both BD and psoriasis should be considered as a multisystem entity with a common physiopathology. Consequently, it is vital to emphasize the importance of the initial psychiatric evaluation.
HusainMStrawbridgeRStokesPYoungA. Anti-inflammatory treatments for mood disorders: systematic review and meta-analysis. J Psychopharm. 2017;31(9):1137–1148. doi:10.1177/0269881117725711.
2.
Roque FerreiraBPio-AbreuJReisJFigueiredoA. Analysis of the prevalence of mental disorders in psoriasis: the relevance of psychiatric assessment in dermatology. Psychiatr Danub. 2017;29(4):401–406. doi:10.24869/psyd.2017.401.
3.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Philadelphia, PA: American Psychiatric Association; 2013.
4.
KimYNaKMyintALeonardB. The role of pro-inflammatory cytokines in neuroinflammation, neurogenesis and the neuroendocrine system in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2016;64:277–284. doi:10.1016/j.pnpbp.2015.06.008.
5.
MalatestaE. Could Biologic Agents Foster Suicide Through Its Potential Antidepressant Mechanism? A Psychodermatological Approach. Poster presented at: The 5th World Psoriasis & Psoriatic Arthritis Conference; 2018; in Stockholm, Sweden.
6.
MuneerA. Mixed states in bipolar disorder: etiology, pathogenesis and treatment. Chonnam Med J. 2017;53(1):1. doi:10.4068/cmj.2017.53.1.1.
7.
SalvadoreGQuirozJMachado-VieiraRHenterIManjiHZarateC. The neurobiology of the switch process in bipolar disorder. J Clin Psychiatry. 2010;71(11):1488–1501. doi:10.4088/jcp.09r05259gre.
8.
ShariqABrietzkeERosenblatJBarendraVPanZMcIntyreR. Targeting cytokines in reduction of depressive symptoms: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. 2018;83:86–91. doi:10.1016/j.pnpbp.2018.01.003.
9.
RosenblatJMcIntyreR. Bipolar disorder and immune dysfunction: epidemiological findings, proposed pathophysiology and clinical implications. Brain Sci. 2017;7(12):144. doi:10.3390/brainsci7110144.
10.
BulutMÇatıSGüneşMKayaMKaplanİÖzkanM. Evaluation of serum inflammatory markers in treatment-resistant manic patients and adequate responder manic patients. Psychiatry Res. 2019;272:73–79. doi:10.1016/j.psychres.2018.12.073.
11.
StroberBGooderhamMde JongE, et al.Depressive symptoms, depression, and the effect of biologic therapy among patients in psoriasis longitudinal assessment and registry (PSOLAR). J Am Acad Dermatol. 2018;78(1):70–80. doi:10.1016/j.jaad.2017.08.051.
12.
OliveiraPCardosoPLimaE, et al.IL-17A, IL-22, IL-6, and IL-21 serum levels in plaque-type psoriasis in Brazilian patients. Mediators Inflamm.2015;2015:1–5. doi:10.1155/2015/819149.
13.
DowlatiYHerrmannNSwardfagerW, et al.A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446–457. doi:10.1016/j.biopsych.2009.09.033.
14.
AleemDTohidH. Pro-inflammatory cytokines, biomarkers, genetics and the immune system: a mechanistic approach of depression and psoriasis. Revista Colombiana de Psiquiatría. 2018;47(3):177–186. doi:10.1016/j.rcp.2017.03.002.
15.
PatelNNadkarniACardwellL, et al.Psoriasis, depression, and inflammatory overlap: a review. Am J Clin Dermatol. 2017;18(5):613–620. doi:10.1007/s40257-017-0279-8.
16.
DalgardFGielerUTomas-AragonesL, et al.The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984–991. doi:10.1038/jid.2014.530.
17.
FarzanfarDDowlatiYFrenchLLowesMAlaviA. Inflammation: a contributor to depressive comorbidity in inflammatory skin disease. Skin Pharmacol Physiol. 2018;31(5):246–251. doi:10.1159/000490002.
18.
AmatyaNGargAGaffenS. IL-17 signaling: the Yin and the Yang. Trends Immunol. 2017;38(5):310–322. doi:10.1016/j.it.2017.01.006.
19.
ChiricozziARomanelliMSaracenoRTorresT. No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents. Expert Opin Drug Saf. 2016;15(12):1653–1659. doi:10.1080/14740338.2016.1228872.
20.
TabarkiewiczJPogodaKKarczmarczykAPozarowskiPGiannopoulosK. The role of IL-17 and Th17 lymphocytes in autoimmune diseases. Arch Immunol Ther Exp (Warsz). 2015;63(6):435–449. doi:10.1007/s00005-015-0344-z.
21.
DavamiMBaharlouRAhmadi VasmehjaniA, et al.Elevated IL-17 and TGF-β serum levels: a positive correlation between T-helper 17 cell-related pro-inflammatory responses with major depressive disorder. Bas Clin Neurosci J. 2016;7(2):6. doi:10.15412/j.bcn.03070207.
JhaMTrivediM. Personalized antidepressant selection and pathway to novel treatments: clinical utility of targeting inflammation. Int J Mol Sci. 2018;19(1):233. doi:10.3390/ijms19010233.
24.
KeshriNNandeeshaHKattimaniS. Elevated interleukin-17 and reduced testosterone in bipolar disorder. Relation with suicidal behaviour. Asian J Psychiatr. 2018;36:66–68. doi:10.1016/j.ajp.2018.06.011.
25.
BrundinLSellgrenCLimC, et al.An enzyme in the kynurenine pathway that governs vulnerability to suicidal behavior by regulating excitotoxicity and neuroinflammation. Trans Psych. 2016;6(8):e865–e865. doi:10.1038/tp.2016.133.
26.
University Health Network, Toronto. A multisite, fixed dose, randomized, double-blind, placebo-controlled 12-week study evaluating the efficacy, safety, and tolerability of adjunctive infliximab for the treatment of bipolar I/II depression. https://clinicaltrials.gov/ct2/show/study/NCT02363738. NLM identifier: NCT02363738. Accessed March 18, 2019.
27.
KappelmannNLewisGDantzerRJonesPKhandakerG. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol Psychiatry. 2016;23(2):335–343. doi:10.1038/mp.2016.167.
28.
BrundinLBrylevaEThirtamara RajamaniK. Role of inflammation in suicide: from mechanisms to treatment. Neuropsychopharmacology. 2016;42(1):271–283. doi:10.1038/npp.2016.116.
29.
KeatonSMadajZHeilmanP, et al.An inflammatory profile linked to increased suicide risk. J Affect Disord. 2019;247:57–65. doi:10.1016/j.jad.2018.12.100.
30.
KooJMarangellLNakamuraM, et al.Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. J Eur Acad Dermatol Venereol. 2017;31(12):1999–2009. doi:10.1111/jdv.14460.
31.
OlivierCRobertPDaihungD, et al.The risk of depression, anxiety, and suicidality in patients with psoriasis. Arch Dermatol. 2010;146(8):891–895. doi:10.1001/archdermatol.2010.186.
32.
PompiliMInnamoratiMErbutoDCostanzoA. Psychiatric comorbidity and suicide risk in patients with psoriasis. Europ Psych. 2016;33:S395–S396. doi:10.1016/j.eurpsy.2016.01.1421.
33.
AkiskalHCetkovich BakmasM. Trastornos Bipolares: Conceptos Clínicos, Neurobiológicos Y Terapéuticos. 1st ed. Buenos Aires: Medica Panamericana; 2006.
34.
LonnbergSLZachariaeC. Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Investig Dermatol. 2014:251. doi:10.2147/ccid.s67534.
35.
SchmutzJ. Apremilast: attention aux idées et comportements suicidaires. Annales de Dermatologie et de Vénéréologie. 2017;144(3):243–244. doi:10.1016/j.annder.2017.01.004.
36.
SchmidtC. Suicidal thoughts end Amgen’s blockbuster aspirations for psoriasis drug. Nat Biotechnol. 2015;33(9):894–895. doi:10.1038/nbt0915-894b.
37.
ToralesJGonzálezIBarriosI. El rol de los fármacos antiinflamatorios en la depresión. Revista Virtual de La Sociedad Paraguaya de Medicina Interna. 2018;5(1):71–77.
38.
RaisonCRutherfordRWoolwineB, et al.A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression. JAMA Psychiatry. 2013;70(1):31. doi:10.1001/2013.jamapsychiatry.4.
39.
CoimbraSSantos-SilvaAFigueiredoA. Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis. Core Evid. 2014:89. doi:10.2147/ce.s33940.
40.
DaneshMKimballA. Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States. J Am Acad Dermatol. 2016;74(1):190–192. doi:10.1016/j.jaad.2015.08.057.
41.
LebwohlMPappKMarangellL, et al.Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018;78(1):81–89.e5. doi:10.1016/j.jaad.2017.08.024.
42.
GooderhamMGavino-VelascoJCliffordCMacPhersonAKrasnoshteinFPappK. A review of psoriasis, therapies, and suicide. J Cutan Med Surg. 2016;20(4):293–303. doi:10.1177/1203475416648323.
BerkMNgFDoddSGoldbergJMalhiG. Do we need to flick the switch? The need for a broader conceptualization of iatrogenic course aggravation in clinical trials of bipolar disorder. Psychiatry Clin Neurosci. 2010;64(4):367–371. doi:10.1111/j.1440-1819.2010.02098.x.
45.
YamaguchiYKimotoSNagahamaTKishimotoT. Dosage-related nature of escitalopram treatment-emergent mania/hypomania: a case series. Neuropsychiatr Dis Treat. 2018;14:2099–2104. doi:10.2147/ndt.s168078.
46.
GriffithsCFavaMMillerA, et al.Impact of ixekizumab treatment on depressive symptoms and systemic inflammation in patients with moderate-to-severe psoriasis: an integrated analysis of three phase 3 clinical studies. Psychother Psychosom. 2017;86(5):260–267. doi:10.1159/000479163.
47.
GiddensJHarnett SheehanKSheehanD. The Columbia-Suicide Severity Rating Scale (C-SSRS): has the “gold standard” become a liability?Innovat Clin Neurosci. 2014;11(9-10):66–80.
48.
Kopschina FeltesPDoorduinJKleinH, et al.Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy. J Psychopharm. 2017;31(9):1149–1165. doi:10.1177/0269881117711708.
